Filing Flows › Nuo Therapeutics (AURX) › Q2 2025
Nuo Therapeutics (AURX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 31, 2025
Nuo Therapeutics (AURX) reported revenue of $700K for the second quarter 2025 (Q2 2025), +92% from a year earlier and +45% from the quarter before. Operating margin was -93.1%, net loss $650K (92.8% of revenue).
Nuo Therapeutics, Q2 2025: revenue $700K (+92% year over year), operating margin -93.1%, net loss $650K, operating cash flow $262K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $700K | +45% | +92% |
| Operating profit | −$652K | — | — |
| Net earnings | −$650K | — | — |
| Operating cash flow | $262K | 144× | — |
| Free cash flow | $261K | — | — |
What changed
Revenue was $700K in Q2 2025, up 92% year over year and up 45% from the previous quarter. Product was the largest line at 89% of revenue. Product added $260K year over year (up 71%), 78% of the total change.
Gross margin was 77.2%, down 4.8 points from a year earlier. Operating costs exceeded revenue by $652K, an operating margin of -93.1%. Operating expenses grew 42% against revenue growth of 92%. The quarter ended with a net loss of $650K, narrower than the previous quarter's $746K loss.
Operating cash flow was $262K. Non-cash charges added back $23K of depreciation and $23K of share-based compensation. Working capital and other items added $866K. Capital expenditures of $2K left free cash flow of $261K.
Questions
What was Nuo Therapeutics' revenue in the second quarter 2025?
Nuo Therapeutics (AURX) reported revenue of $700K for the second quarter 2025 (Q2 2025), +92% from a year earlier and +45% from the quarter before.
Was Nuo Therapeutics profitable in the second quarter 2025?
Operating loss was $652K (-93.1% of revenue) and net loss $650K.
Source: Nuo Therapeutics 10-Q on SEC EDGAR.